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Abstract: Uveal melanoma is considered a rare disease but it is the most common intraocular
malignancy in adults. Local treatments are effective, but the systemic recurrence rate is unacceptably
high. Moreover, once metastasis have developed the prognosis is poor, with a 5-year survival rate
of less than 5%, and systemic therapies, including immunotherapy, have rendered poor results.
The tumour biology is complex, but angiogenesis is a highly important pathway in these tumours.
Vasculogenic mimicry, the ability of melanomas to generate vascular channels independently of
endothelial cells, could play an important role, but no effective therapy targeting this process has been
developed so far. Angiogenesis modulates the tumour microenvironment of melanomas, and a close
interplay is established between them. Therefore, combining immune strategies with drugs targeting
angiogenesis offers a new therapeutic paradigm. In preclinical studies, these approaches effectively
target these tumours, and a phase I clinical study has shown encouraging results in cutaneous
melanomas. In this review, we will discuss the importance of angiogenesis in uveal melanoma, with
a special focus on vasculogenic mimicry, and describe the interplay between angiogenesis and the
tumour microenvironment. In addition, we will suggest future therapeutic approaches based on
these observations and mention ways in which to potentially enhance current treatments.
Keywords: uveal melanoma; angiogenesis; immunotherapy; tumour microenvironment;
vasculogenic mimicry
1. Introduction
Uveal melanoma (UM) is a malignant tumour that arises in the melanocytes located in the uveal
tract [1]. In 85–90% of cases the choroid is involved, while in the remaining 10–15% the tumour will
arise in the iris and ciliary body [2–4]. It is considered a rare cancer, with an estimated incidence of
4.9–5.2 cases per million in the United States [5], which has remained stable in the past 20 years [6].
In Europe, the incidence seems to be highest in the Northern countries, with an incidence rate of more
than 8 cases per million in Norway and Denmark [7]. However, in Southern countries, such as Spain
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or Italy, the incidence is less than 2 cases per million. This pattern is interestingly in contrast to what is
observed in cutaneous malignant melanoma, probably due to phenotypic and racial disparities [8].
Over 95% of patients have disease confined to the eye upon diagnosis [9], mostly owing to its
early clinical manifestations [10]. However, up to 50% of patients will develop metastasis [4], mostly to
the liver [9]. Many factors have been associated to an increased risk of metastasis, including clinical
factors such as tumour thickness, ciliary body location, or increasing tumour diameter [4]. More
recently, molecular and cytological factors such as monosomy of chromosome 3, additional copies
of chromosome 8 [11], and BRCA1 associated protein (BAP1) mutations [12], have been related to
decreased survival. On the other hand, Splicing factor 3B subunit 1 (SF3B1) and Eukaryotic translation
initiation factor 1A (EIF1AX) mutations seem to confer improved survival [13–16].
The prognosis of metastatic UM remains dismal, with a median overall survival (OS) of less than
a year in most cases [1,17,18]. Moreover, survival rates seem to have remained stable over the past
40 years, reflecting the lack of current effective systemic strategies [1,19,20]. Indeed, the objective
response rates (ORRs) of commonly used chemotherapies are unacceptably low [21]. Single-agent
chemotherapies, such as fotemustine [22] or dacarbacine [23], have ORRs of 2.4% and 8%, respectively,
with median progression-free survivals of less than 3 months in both cases. In addition, combined
chemotherapy regimens, such as dacarbazine–treosulfan [24] or gemcitabine–treosulfan [25] have also
shown disappointing results, with ORRs of 0% and 4.2%, respectively.
The emergence of immunotherapy has changed the natural history of cutaneous malignant
melanoma. Indeed, anti-programmed death ligand 1 (PDL1) and anti-programmed death 1 (PD1)
antibody monotherapy have shown to significantly improve survival in metastatic cutaneous
melanoma compared to standard chemotherapy [5,26,27]. However, the most intriguing question
of immunotherapy in this tumour is whether the durable complete responses observed with these
treatments could translate into a possibility for cure, in a clinical setting which was previously
considered incurable [28]. In a pooled-analysis of more than 1800 patients with advanced cutaneous
melanoma treated with ipilimumab, an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal
antibody, the survival curve seemed to plateau at 21% starting at year 3, implying that one-fifth
of patients could achieve long-term survival and could eventually be cured with immunotherapy
alone [29]. Longer follow-up of the above-mentioned anti-PD1 and anti-PDL1 trials are eagerly awaited
to study this phenomenon further. Moreover, combining anti-CTLA4 and anti-PD1 therapies has
proved to significantly increase survival compared to anti-PD1 monotherapy [30]. More interestingly
so, the survival curves seem to plateau at more than 50% [31], although this will require further
confirmation with longer follow-up.
However, these encouraging results have not been reproduced in UM. In two phase II trials
that studied the role of ipilimumab in metastatic UM, the ORR varied from 0% to 7.7%, with an OS
of 6.8 months in this population [32,33]. Anti-PD1 and anti-PDL1 did not increase efficacy in this
patient population, with an ORR of 3.6% and a median OS of 7.6 months [34]. Lastly, combining both
antibodies rendered a disappointing ORR of 12%, with a median OS of 12.7 months [35].
UM develops in one of the most capillary-rich tissues of the body and is disseminated
haematogenously. Most UM cell lines, but not normal melanocytes, strongly synthesize and secrete
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) during cell
culture [36]. As we will thoroughly discuss, vascular abnormalities facilitate immune evasion [37] and
angiogenic signatures are frequently enriched in tumours with resistance to checkpoint inhibitors [38].
Indeed, VEGF and other angiogenic factors play an important role in modulating the immune
system directly by suppressing dendritic cell maturation [39], inhibiting T-cell effector response [40],
and recruiting myeloid derived suppressor cells [41].
These assumptions suggest that a combined therapeutic approach of immunotherapy and
antiangiogenic drugs could potentially overcome the adverse microenvironment of UM, and therefore
increase the efficacy of checkpoint inhibitors.
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2. Angiogenesis in Melanoma
Angiogenesis is a hallmark of cancer [42], and is defined as the development of new blood
vessels from a pre-existing vascular network in order to supply the nutritional and metabolic demands
of tumours [43]. Progression of benign lesions to malignant tumours often requires an angiogenic
switch [44], understood as a time-restricted event during tumour progression where the balance
between pro- (such as vascular endothelial growth factor-A (VEGF-A)) and anti-angiogenic factors
(such as thrombospondin-1 (TSP-1)) tilts towards a pro-angiogenic outcome [45], eventually leading
to the formation of new blood vessels [43]. Due to the chronic activation of pro-angiogenic factors,
the resulting vessels often acquire an aberrant morphology [42,43].
In addition to endothelial cells, pericytes seem to play an essential role in regulating vessel
maturation, stabilization, quiescence and function in cancer [46]. Pericytes are branched, contractile
cells present in capillaries that physiologically regulate microvascular blood flow [47]. They are believed
to contribute to the aberrant morphology of the resulting vessels [48]. Furthermore, pericytes seem to
regulate cell metastasis. Indeed, pericyte dysfunction results in an increase in distant metastasis [49,50].
Factors involved in regulating their functions include platelet-derived growth factor-B (PDGF-B) [51],
angiopoietin 1 and 2 (Ang1 and Ang2) [52], transforming growth factor B (TGF-B) [47], and vascular
endothelial growth factor (VEGF) [52].
Finally, apart from endothelial cells and pericytes, macrophages seem to be major contributors
to angiogenesis. In 2001, tumour infiltrating macrophages (TAMs) were found to be associated to
worse prognosis in UM [53], and Bronkhorst et al. demonstrated in 2010 that this was mainly due to
polarized M2 macrophages [54]. These macrophages are associated to immunosuppressive functions
and are proangiogenic cells [55–57]. Interestingly, Bronkhorst et al. found that a high infiltration of
M2 macrophages was correlated to monosomy 3 and increased microvascular density in UM [54].
Additionally, macrophages present in choroidal neovascularization specimens express VEGF, which
further supports a role of these cells in UM angiogenesis [58].
Angiogenesis has been shown to be an essential feature in the transition from radial to vertical
growth in cutaneous melanoma, a necessary step before invasion and metastasis [59–62]. Moreover,
more vascularized tumours entail a worse prognosis [63,64], resulting in a higher risk of systemic
spread and decreased survival [65]. Highly vascularized UM tumours are also more aggressive and
convey a worse prognosis [66,67]. Moreover, our group has applied a well-established molecular
signature for angiogenesis to the expression data available from the UM The Cancer Genome Atlas
(TCGA). The “BIOCARTA_VEGF_PATHWAY” signature is composed of 29 different genes related to
angiogenesis, including Hypoxia-inducible factor 1-alpha (HIF1A), the eukaryotic translation initiation
factor (EIF), VEGFA, and von Hippel Lindau (VHL), amongst others. Tumours in the TCGA that relapse
systemically show a much higher angiogenesis enrichment score than non-relapsed patients (Figure 1).
Differences in disease-free survival (DFS) when comparing high vs. low angiogenesis enrichment
scores (Figure 2A) were statistically significant in UM patients. However, DFS was not significant when
we compared signature high vs. low using primary tumours included in the cutaneous melanoma
dataset from the TCGA (Figure 2B).
The hypoxic microenvironment of these tumours leads to the release of hypoxia-inducible
factor 1 (HIF-1), which in turn induces VEGF, Ang-2, matrix metalloprotease 14 (MMP14),
and angiogenin [68–71]. Other important pro-angiogenic factors involved in advanced melanoma
include interleukin-8 (IL-8) [72–74] and PDGF [61,69,75,76]. High levels of Ang2 [77], VEGF [78],
IL-8, and basic fibroblast growth factor (bFGF) [79] have been correlated to poor overall survival and
increased risk of recurrence [80,81], while declining levels of these factors following systemic treatment
seem to correlate to response [82]. Moreover, inhibition of the HIF pathway with arylsulfonamide
64B in animal UM models results in tumour regression and improved survival [83], and inhibition of
VEGF-A with bevacizumab in both mouse and human uveal melanoma inhibits the establishment of
micrometastasis [84], further reflecting its importance [83].
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Figure 1. Angiogenesis enrichment score comparing relapsed vs. non-relapsed tumours. Scores were 
generated from expression data by gene set variation analysis (Gene Set Variation Analysis (GSVA) 
function). The gene set “Biocarta VEGF Pathway” from MSigDatabase (which includes genes related 
to hypoxia, blood vessels formation, and pro-angiogenic factors) was used 
(http://software.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_VEGF_PATHWAY). Groups 
were compared by non-parametric Wilcoxon rank test. Data were extracted from The Cancer Genome 
Atlas (TCGA) database through cBioPortal (TCGA-UVM, 80 primary samples); expression data were 
downloaded as normalized Fragments Per Kilobase of exon per million fragments Mapped (FPKM) 
values and log2 transformed. VEGF: vascular endothelial growth factor. 
 
Figure 2. Disease-free survival for uveal melanoma (UM) (A) and cutaneous melanoma (B) from 
patients included in the TCGA, clustered into the top 50% (high angiogenesis enrichment score) vs. 
the bottom 50% (Low angiogenesis enrichment score). The cut-off used for generating high and low 
groups was the median enrichment score. The gene set used for scores was the same as for Figure 1. 
Data were extracted from the TCGA database through cBioPortal; 60 primary UM samples, 99 
primary cutaneous melanoma samples. 
The hypoxic microenvironment of these tumours leads to the release of hypoxia-inducible factor 
1 (HIF-1), which in turn induces VEGF, Ang-2, matrix metalloprotease 14 (MMP14), and angiogenin 
A B 
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hypoxia, blood vessels formation, and pro-angiogenic factors) was used (http://software.broadinstitute.
org/gsea/msigdb/cards/BIOCARTA_VEGF_PATHWAY). Groups were compared by non-parametric
Wilcoxon rank test. Data were extracted from The Cancer Genome Atlas (TCGA) database through
cBioPortal (TCGA-UVM, 80 primary samples); expression data were downloaded as normalized
Fragments Per Kilobase of exon per million fragments Mapped (FPKM) values and log2 transformed.
VEGF: vascular endothelial growth factor.
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The molecular pathways involved in angiogenesis in melanoma are complex and beyond the
scope of this review [85]. Notch1 seems to be increasingly important, especially in cutaneous
melanoma. Indeed, in a review of 114 primary cutaneous melanoma carried out by Murtas et al. [86],
the overexpression of Notch1 in both tumour and endothelial cells was associated to microvascular
density. Notch1 seems to upregulate mitogen-activated protein kinase (MAPK) through CD133,
which in turn transdifferentiates into endothelial-like phenotypes, therefore promoting growth and
angiogenesis [87]. In UM, however, there is no established direct relationship between the Notch
signalling pathway and angiogenesis. Nevertheless, hypoxia does seem to promote growth and
invasion of uveal melanoma cell lines through the activation of Notch and MAPK [88,89].
Another important role of Notch1 seems to be its involvement in vascular mimicry [90], which we
will discuss in the following section.
Vasculogenic Mimicry
Vasculogenic mimicry is referred to as the process by which aggressive melanoma cells generate
vascular channels independently of endothelial cells [46]. This was first described by Maniotis et al. 1999
in cutaneous and UM tissue sections [91]. The authors observed interconnected loops of extracellular
matrix containing some red blood cells, with no evidence of endothelial cells. These patterns were more
common in highly invasive melanomas, whereas normal melanocytes or poorly invasive cells were unable
to generate such channels [91]. In 2008, Frenkel et al. used laser scanning confocal angiography with
indocyanine green to demonstrate blood circulation through leakage [92]. Since this initial description,
vasculogenic mimicry has been found in many other tumours and seems to be correlated to poor tumour
differentiation, lymph node involvement, distant metastasis, and TNM stage [93], and therefore entails a
decreased survival [93,94].
The molecular processes and mechanisms involved in vasculogenic mimicry are elusive, and much
remains to be understood [95,96]. The process is triggered by a reversion of the melanocytic tumour
cells to a pluripotent embryonic-like genotype [91,97,98]. The acquisition of these stem-like properties
seems to be mediated by the induction of the epithelial–mesenchymal transition (EMT), as initially
observed in mammary epithelial cells [99]. Indeed, coexpression of epithelial and mesenchymal
markers has been observed in cutaneous melanoma cells engaged in vasculogenic mimicry [100,101].
Additionally, a significant overexpression of EMT transcription factors involved in both the acquisition
of stem cell-like properties and vasculogenic mimicry have been observed in different tumours, such
as Nodal in murine melanoma and human cutaneous melanoma [102–105], Twist in hepatocellular
carcinoma [106–108], Bcl-2 in human melanoma and hepatocellular carcinoma [108,109], Zinc-finger
E-box binding homeobox (ZEB) in hepatocellular, pancreatic, and colorectal carcinoma, [110–112], or
Snail in human breast and oral squamous cell carcinomas [113,114], amongst others. Despite this
relationship not being directly established in UM, the expression of EMT-associated factors does
promote invasion and growth [115], which we believe could be partly explained by their role in
vasculogenic mimicry, as has been demonstrated in other tumours. Only a small subset of cells, globally
termed melanoma cancer stem cells (MCSCs), that are preferentially localized in the perivascular
niches of cutaneous melanomas and express stem cell markers, seem to be involved in vasculogenic
mimicry [116].
MCSCs involved in the formation of tubules in cutaneous melanoma cell lines highly express
vascular endothelial-cadherin (VE-cadherin) [117], a central actor in vasculogenic mimicry. Indeed,
downregulation of this molecule in both cutaneous and UM lines completely abrogates vasculogenic
mimicry [117,118]. VE-cadherin is induced during EMT transition [119] and upregulates transforming
growth factor β (TGF-β) in breast cancer cells. Additionally, VE-cadherin is colocalized with EphA2 at
cell–cell adhesions and regulates EphA2 at the cell membrane in both uveal and cutaneous melanoma
lines, by mediating its ability to become phosphorylated through interactions with its membrane bound
ligand, ephrin-A1 [120]. The exact molecular pathways involved in the regulation of this complex
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interplay remain unknown, although these findings, along with others [121] evidence the importance
of intracellular phosphorylation in vasculogenic mimicry.
Microarray gene chip analysis has revealed increased expressions of laminin 5, membrane type
1-matrix metalloproteinases (MT1-MMP), and MMP-1, -2, -9, and -14 in aggressive metastatic melanoma
cells compared to poorly aggressive ones, and the inhibition of the interaction between laminin-5
and MMP-2 and MT1-MMP with specific antibodies inhibits the formation of the tubular network,
suggesting a strong implication of these components in vasculogenic mimicry [122]. The overexpression
of MT1-MMP and MMP-2 is regulated by phosphoinositide 3-kinase (PI3K), and specific inhibitors
of PI3K are able to abrogate vasculogenic mimicry in both uveal and cutaneous melanoma cells by
decreasing the levels of MT1-MMP and MMP-2 [123].
Furthermore, the hypoxic microenvironment of melanomas seems to be an additional trigger
of vasculogenic mimicry [124]. Mouse melanoma B16 cells implanted in the ischemic limbs of mice
have more vasculogenic mimicry channels than controls, with a higher expression of HIF-1, MMP-2,
MMP-9, and VEGF [125,126]. Indeed, vasculogenic mimicry seems to be partly mediated by vascular
endothelial growth factor receptor 1 (VEGFR-1), as was shown by Frank et al. in ABCB5+ melanoma
xenografts [127]. However, a second, VEGF-independent mechanism is also able to trigger vasculogenic
mimicry, mediated by the platelet EC adhesion molecule (PECAM-1), whose expression is repressed
by the neural crest specifier AP-2α [128].
The relative contribution of the aforementioned mechanisms of tumour blood supply to disease
progression are unknown. However, in a study performed in mouse melanoma xenographs, mosaic
vessels, vasculogenic mimicry, and endothelium-dependent vessels were observed in all stages of
tumour development. However, vasculogenic mimicry seemed to be the predominant pattern in early
stages of disease, while this was replaced by endothelium-dependent vessels in later stages of disease
development [129]. In intraocular melanoma models, the three types of microcirculation were also
observed, but endothelium-dependent vessels were more common in larger tumours while vascular
mimicry seemed to be predominant in smaller lesions [130]. Therefore, vasculogenic mimicry seems to
play a predominant role in early stages of disease development, both in cutaneous and UM. These
observations seem to be contradicted by the initial findings of Maniotis et al. and Chang et al. [91,131],
where larger tumours seemed to be richer in matrix-embedded channels. Whether vasculogenic
mimicry is a time-dependent event in disease progression or simply identifies inherently more
aggressive tumours is unclear.
Folberg et al. demonstrated that UM that presented vasculogenic mimicry patterns had an
upregulation of genes related to differentiation and suppression of proliferation, and a downregulation
of genes related to promotion of invasive and metastatic behaviour [132]. These findings are
counterintuitive given the worse prognosis of melanoma patients presenting with his pattern. However,
the authors hypothesize that these findings could explain the chemoresistance observed in these
tumours and the late metastatic recurrences of some of these patients.
3. Antiangiogenic Drugs in Uveal Melanoma
Based on the preclinical evidence previously discussed, targeting angiogenesis in UM seems to be
an attractive and potentially effective strategy [133]. However, results of the clinical trials that have
investigated this matter have been disappointing so far (see Table 1), although they do seem to be more
active than in cutaneous melanoma. Most antiangiogenic drugs render no response [134–139] and in the
largest trial performed to date, the best observed response rate with sorafenib was 1.7% [140]. However,
cabozantinib showed higher PFS in uveal melanoma patients compared to cutaneous melanoma [139].
This observation is based on indirect comparisons and must therefore be taken with caution.
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Table 1. Selected clinical trials with antiangiogenic drugs in metastatic uveal melanoma.








2011 [141] Phase II 5 Bev-IFNα2b
VEGF (Bev, IFNα2b),
bFGF (IFNα2b) 10.8 4.5 20 66
Tarhini 2011 [134] Phase II 9 Aflibercept VEGF-A, -B, PlGF 19 5.7 0 78
Zeldis 2009 [135] Phase II 16 Lenalidomide VEGF, others NR NR 0 44
Solti 2007 [136] Pilot 6 Thalidomide-IFNα2b VEGF, bFGF, TNFα 9 3.6 0 17





11 4 0 45
Mahipal 2012 [142] Pilot 20 Sunitinib VEGFR-1–3, PDGFR,c-Kit, FLT-3, RET 8.2 4.2 5 65
Hofmann 2009 [138] Phase II 12 Imatinib ABL, KIT, PDGFR 6.8 NR 0 8
Fruehauf 2011 [143] Phase II 3 Axitinib VEGFR-1, -2, -3 NR NR 33 NR
Daud 2017 [139] Phase II 23 Cabozantinib c-Met, VEGFR-2, c-Kit,RET, FLT-3, TIE2, AxI 12.6 4.8 0 61
Piperno-Neumann
2013 [144] Phase II 35 Bev-Temozolamide VEGF 12 3 0 26




14.8 5.5 1.7 67.8
Abbreviations: N: number of patients; mOS: median overall survival; mPFS: median progression-free survival; m:
months; ORR: objective response rate; DCR: disease control rate; Bev: bevacizumab; IFN: interferon; PIGF: placental
growth factor; VEGFR: vascular endothelial growth factor receptor; TNF: tumour necrosis factor.
Some antiangiogenic drugs do seem to be able to produce disease stabilization in more than 50%
of patients [134,139–142], albeit for a short period of time in most cases. Moreover, one must bear in
mind that the number of patients included in these trials is low, with less than 20 patients in most
cases, which hinders the generalizability of the data (see Table 1). Some have questioned whether the
stabilizations observed were in fact due to the antiangiogenic effects of these drugs or were simply
reflecting the natural history of this disease. In order to try to answer this question, Scheulen et al.
carried out the STEAM study, a randomized phase II trial, in which all patients were initially treated
with sorafenib for 56 days in a run-in period. Patients with stable disease were then randomized to
continue on sorafenib or placebo. The trial demonstrated a significant increase in progression-free
survival (5.5 vs. 1.9 months, Hazard Ratio (HR) 0.527, p = 0.0079) in patients that continued on
sorafenib. Cross-over to sorafenib was allowed following progression to placebo. That might explain
that there were no differences observed in overall survival (OS).
Therefore, new approaches are needed in order to optimize outcomes with antiangiogenic therapies
in UM.
One of the main concerns in the current approaches is that antiangiogenic strategies target
molecules that are mainly involved in endothelium-mediated angiogenesis, leaving vasculogenic
mimicry aside. However, as we have discussed, vasculogenic mimicry seems to be present in more
aggressive melanomas, and although its biological implication is unclear, its inhibition could have
a potential therapeutic role. Indeed, van der Schaft et al. demonstrated that using three angiogenic
inhibitors (anginex, TNP-470 and endostatin) in human melanoma as compared to human endothelial
cell lines inhibited angiogenesis in endothelial lines but did not inhibit vasculogenic mimicry in the
melanoma lines. A further analysis revealed a differential expression of two endostatin receptors that
could explain these observations [145]. Targeting vasculogenic mimicry, therefore, should be pursued
and has been attempted with different approaches in preclinical melanoma models:
• Genistein, an isoflavone present in soybeans, is able to inhibit vasculogenic mimicry in uveal
melanoma C918 cell lines by reducing the expression of VE-cadherin [146].
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• Pevonedistat, a selective and potent inhibitor of NEDD8-activating enzyme E1 subunit 1 (NAE1),
an enzyme involved in neddylation, is able to repress the cancer stemness properties of UM cell
lines, and could therefore potentially interfere with vasculogenic mimicry [147].
• Fasudil, a Rho kinase inhibitor, is able to reduce tumour growth in melanoma cell lines and
melanoma mice models by inhibiting vasculogenic mimicry [148].
• Nicotinamide, the amide form of vitamin B3 (niacin), effectively targets vasculogenic mimicry
by downregulating VE-cadherin in cutaneous melanomas cell lines. However, melanoma cells
seemed to acquire an increased invasion capacity [149].
• A chemically modified tetracycline is able to inhibit MMP-2 and -9 in addition to laminin 5
in both cutaneous and uveal melanoma cell lines. Moreover, the expression of vasculogenic
mimicry-associated genes is also inhibited [150].
• Cilenglitide, a potent inhibitor of αv integrins activation, reduces extracellular matrix invasion,
vasculogenic mimicry, and secretion of MM9 by selectively targeting αvβ5 integrin in human
cutaneous melanoma cell lines [151].
• Thalidomide, a drug with antiangiogenic and immunomodulatory properties, is able to decrease
the number of vasculogenic mimicry tubules and reduce the protein expression of MMP-2,
MMP-9, VEGF, proliferating cell nuclear antigen (PCNA), and nuclear factor-κβ (NF-κβ) in
murine cutaneous melanoma cell lines [152].
• PARP inhibitors suppress the metastatic potential of some human and murine melanoma cells, due
in part to the inhibition of vasculogenic mimicry mediated by the downregulation of VE-cadherin
and the inhibition of the EMT pathway [153].
• Novel molecules, such as CVM-1118, seem to inhibit vasculogenic mimicry by targeting essential
pathways involved in the process in human melanoma cells [154].
Targeting pericytes is another plausible therapeutic opportunity [155] and could help overcome
tumour resistance to other drugs [156]. The proteoglycan NG2 stimulates the proliferation, motility,
and migration of pericytes, and is crucial in the early stages of neovascularization [157]. Inhibition
of pericytes via NG2 in UM xenografts decreases neovascularization and tumour volume, thereby
rendering it a potential target [158,159].
Another possible approach would be a combination of antiangiogenic drugs with other therapies.
For instance, combining bevacizumab with radiotherapy in UM mice models was shown to significantly
decrease tumour growth compared to either bevacizumab or radiotherapy alone [160]. Combining
antiangiogenic drugs with immunotherapy could have a potentially synergistic effect, as we will
discuss in the following section.
4. The Potential Benefit of Combining Antiangiogenic and Immune Strategies
UM has traditionally been considered an immune privileged tumour, in a manner that closely
parallels the microenvironment of the eye [161,162]. However, immune infiltration is found in the
primary tumour [163,164], and its presence is associated to decreased survival [164], contrary to what
is observed in other tumours [165]. Interestingly, metastatic UM seems to have a different lymphocytic
composition compared to metastatic cutaneous melanoma, with predominant CD4+ lymphocytes
instead of CD8+ lymphocytes (more commonly observed in cutaneous melanoma) [166]. Moreover,
in contrast to most other tumours, the cytotoxic phenotype does not seem to confer better prognosis in
UM [167], possibly reflecting the dominant immunosuppressive microenvironment [168,169]. UM also
substantially differs from cutaneous melanoma in other aspects. For instance, the tumour mutation
burden (TMB) (a surrogate for tumour antigenicity) of cutaneous melanoma is one of the highest
among all tumours studied by the TCGA, whereas UM shows one of the lowest (Figure 3). However,
when considering CD8A and PDL1 expression (a surrogate for tumour immunogenicity), almost 50%
of cutaneous melanomas are considered CD8Ahigh/PDL1high, whereas the same percentage of UM
are considered CD8Alow/PDL1low, reflecting a more immunosuppressed tumour microenvironment
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(Figure 4A,B). Interestingly the behaviour of UM and cutaneous melanoma in the highest and lowest
CD8A/PDL1 quart differs substantially. Interestingly, CD8Alow/PDL1low cutaneous melanoma show a
dismal prognosis, whereas CD8Ahigh/PDL1high UM convey a worse prognosis (Figure 4C).
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the TCGA database. (A,B) Less than 25% of UM tumo rs expr ss high CD8A and PDL1, whereas close
to 50% of cutaneo s melanoma tu our samples express high levels of both genes. (C) Kaplan–Meier
PFS curves of UM and cutaneous melanoma with the highest (red) and lowest (blue) quartile of
expression of both CD8A and PDL1. Highly immunogenic tumours seem to have better prognosis in
cutaneous melanoma, although the opposite effect is seen in UM, even showing that all patients in the
CD8Ahigh/PDL1high-quartile experience disease relapse.
A substantial number of UMs show no lymphocytic infiltration on histologic sections [164].
The immune infiltrate in UM seems to be related to genetic alterations, with the lack of BAP1 mutations
showing a richer T-cell infiltration [170]. Another mechanistic explanation for this is the lack of adhesion
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of lymphocytes to the newly formed vessels [171]. Indeed, leukocytes require a number of molecules in
order to roll, adhere, and finally transmigrate into the tumour microenvironment, including selectins,
PECAM-1, intracellular adhesion molecular-1, -2 (ICAM-1, ICAM-2, respectively), and vascular cell
adhesion molecular -1 (VCAM-1), amongst others [172]. Intratumoural cutaneous melanoma vessels
have a decreased expression of P-selectin, VCAM-1, E-selectin, and ICAM-1, although the normal
adjacent tissues have normal expression of these molecules [173–176]. The downregulation of these
adhesion molecules could be mediated by the overexpression of VEGF [176]. Additionally, the tumour
endothelium expresses molecules that can block T-cell infiltration in different tumour types (including
melanoma), such as FasL [177], endothelin B receptor (ETBR), and endothelin-1 [178].
In addition to the expression of certain adhesion molecules on the endothelium, a chemoattractant is
necessary to correctly recruit lymphocytes, especially chemokines that signal through the C-C chemokine
receptor 5 (CCR5) and C-X-C Receptor 3 (CXCR3) axes [171]. Indeed, the co-expression of both molecules
leads to a high CD8+ T-cell infiltration in cutaneous melanoma [179,180], and upregulation of both
CCR5/CXCR3 is associated to greater response to different immunotherapies, including checkpoint
inhibitors [181] and adoptive cell therapy [182]. Interestingly, the downregulation of these molecules
or their corresponding ligands is correlated to disease progression [173,183].
Little is known about the interaction of vessels formed during vasculogenic mimicry and leukocytes.
Nevertheless, studies have shown that the expression of some adhesion molecules on these vessels,
such as PECAM-1 [128], possibly allowing circulating cells to interact with these tumour vessels. This
raises the possibility of the tumour being able to regulate its own microenvironment by recruiting
specific immune cells [171]. This area of research is currently under active investigation.
Highly angiogenic melanomas are more resistant to checkpoint inhibitors [38], probably due to
the close relationship between aberrant cancer angiogenesis and immunosuppression [184]. Indeed,
the tumour microenvironment, often characterized by hypoxia and high interstitial fluid pressure [185],
could not only enhance an immunosuppressive microenvironment but also reduce the effectiveness of
immunotherapy [37]. Moreover, VEGF (along with other angiogenic factors) plays a crucial role in
modulating the immune system and fostering an immunosuppressive microenvironment: it directly
suppresses dendritic cell maturation breast and colon carcinomas [39,186], inhibits T-cells by enhancing
PD-1 and other inhibitory checkpoints in colon carcinomas [40,187], disrupts the normal differentiation
of haematopoietic precursor cells [188], and recruits immunosuppressive cells such as T-cells [189] and
myeloid derived suppressor cells [41,190].
Therefore, selectively targeting VEGF could not only inhibits angiogenesis but also change the
tumour microenvironment, making it more “immunoresponsive” [185]. However, a more judicious
use of antiangiogenic therapies would not only target angiogenesis but could give rise to tumour
vessels with structural and functional phenotypes that are closer to non-malignant tissues, a process
commonly referred to as vascular normalization [191]. This could subsequently result in an increased
accumulation of cytotoxic T-cells [192], thereby improving the efficacy of checkpoint inhibitors.
The strategy of combining immune-checkpoint inhibitors with antiangiogenic drugs has
been studied in other tumours [193]. For instance, three recent phase III studies combining
anti-PD1/PDL1 with antiangiogenic therapies showed promising results in advanced renal cell
carcinoma [194,195]. Pembrolizumab and axitinib increased overall survival compared to standard
first-line sunitinib [195], and the combination of avelumab–axitinib increased progression-free
survival [194]. Atezolizumab–bevacizumab also showed an increase in progression-free survival,
although the survival data were still immature. In non-small cell lung cancer, the combination of
chemotherapy with bevacizumab and atezolizumab increased progression-free survival and overall
survival compared to chemotherapy and bevacizumab alone [196,197].
Based on these preclinical observations, Hodi et al. 2014 carried out a phase I clinical trial in patients
with advanced cutaneous melanoma that received a combination of ipilimumab and bevacizumab.
They observed a disease control rate of 64.7% and an OS of 25.1 months. More interestingly, however,
on-treatment tumour biopsies revealed activated vessel endothelium with increased expression of
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E-selectin and increased infiltration of CD8+ T-cells [198]. Although angiogenesis seems to confer
worse prognosis to UM when compared to cutaneous melanoma, to the best of our knowledge no
clinical trial has been undertaken to study the benefits of combining antiangiogenic therapies with
immunotherapy. The Grupo Español de Melanoma (GEM), a Spanish collaborative group, has recently
designed a phase II, single-arm study in patients with metastatic UM who will be treated with the
combination of durvalumab, an antiPD-L1 inhibitor, and cediranib, a multikinase inhibitor of VEGFR,
PDGFRβ, KIT, and FLT-1 and -2. The primary endpoint is to evaluate the efficacy and response rate of
the combination of cediranib and durvalumab in patients with metastatic UM with biopsiable disease
at baseline, in first line or after failure to first-line systemic or liver-directed therapies. Five centres will
be involved, and 18 patients are expected to be included, although the total number of patients may
increase to 27 if the ORR > 20%.
5. Conclusions
In summary, angiogenesis plays an essential role in the development and progression of UM,
and the exact implication of vasculogenic mimicry is still unclear, but could potentially play an
important role. The efficacy of antiangiogenic drugs is still insufficient. Given the close relationship
between angiogenesis and the immune microenvironment, combining antiangiogenic therapies and
checkpoint inhibitors offers a potentially groundbreaking strategy. Nevertheless, we believe a deeper
knowledge of vasculogenic mimicry is urgently needed. As we have seen, no effective strategy has
been developed thus far and current antiangiogenic therapies not only do not target this pathway
but could even overactivate it. This, in turn, could render antiangiogenic combination therapies
ineffective. Moreover, targeting vasculogenic mimicry could not only contribute to the normalization of
blood supply but also modulate the tumour microenvironment, therefore rendering immune therapies
more effective.
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